Comparing the effectiveness of depot buprenorphine (buvidal injection) and buprenorphine/naloxone (suboxone) treatment following custody release - a retrospective cohort study

References

• Australian Bureau of Statistics. (2021). Snapshot of Australia. https://www.abs.gov.au/statistics/people/people-and-communities/snapshot-australia/latest-release
   Google Scholar
• Barnett, A., Savic, M., Lintzeris, N., Bathish, R., Arunogiri, S., Dunlop, A. J., Haber, P., Graham, R., Hayes, V., & Lubman, D. I. (2021). Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in Australia. Drug and Alcohol Dependence, 227, 108959. https://doi.org/10.1016/j.drugalcdep.2021.108959
   PubMed Web of Science ®Google Scholar
• Cheng, A., Badolato, R., Segoshi, A., McDonald, R., Malone, M., Vasudevan, K., Badiei, B., Sugarman, A., Macdonald, R., Mangat, J., Giftos, J., Lee, J. D., & Tofighi, B. (2022). Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: An in-depth qualitative study. Addiction Science & Clinical Practice, 17(1), 4. https://doi.org/10.1186/s13722-022-00288-4
   PubMed Web of Science ®Google Scholar
• Curtis, M., Berk, J., Larney, S., Rich, J. D., & Stoové, M. (2022). Switching of opioid agonist treatment modality during imprisonment: A novel marker for increased support need during and following release from prison. The International Journal on Drug Policy, 100, 103572. https://doi.org/10.1016/j.drugpo.2021.103572
   PubMed Web of Science ®Google Scholar
• Curtis, M., Dietze, P., Aitken, C., Kirwan, A., Kinner, S. A., Butler, T., & Stoové, M. (2018). Acceptability of prison-based take-home naloxone programmes among a cohort of incarcerated men with a history of regular injecting drug use. Harm Reduction Journal, 15(1), 1–9. https://doi.org/10.1186/s12954-018-0255-5
   PubMedGoogle Scholar
• Curtis, M., Winter, R. J., Dietze, P., Wilkinson, A. L., Cossar, R. D., Stewart, A. C., Agius, P. A., Butler, T., Aitken, C., Kirwan, A., Walker, S., & Stoové, M. (2022). High rates of resumption of injecting drug use following release from prison among men who injected drugs before imprisonment. Addiction, 117(11), 2887–2898. https://doi.org/10.1111/add.15971
   PubMed Web of Science ®Google Scholar
• Fox, A. D., Maradiaga, J., Weiss, L., Sanchez, J., Starrels, J. L., & Cunningham, C. O. (2015). Release from incarceration, relapse to opioid use and the potential for buprenorphine maintenance treatment: A qualitative study of the perceptions of former inmates with opioid use disorder. Addiction Science & Clinical Practice, 10(1), 1–9. https://doi.org/10.1186/s13722-014-0023-0
   Google Scholar
• Haight, B. R., Learned, S. M., Laffont, C. M., Fudala, P. J., Zhao, Y., Garofalo, A. S., Greenwald, M. K., Nadipelli, V. R., Ling, W., & Heidbreder, C. (2019). Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 393(10173), 778–790. https://doi.org/10.1016/S0140-6736(18)32259-1
   PubMed Web of Science ®Google Scholar
• Johnson, B., Flensburg, O. L., & Capusan, A. J. (2022). Patient perspectives on depot buprenorphine treatment for opioid addiction–a qualitative interview study. Substance Abuse Treatment, Prevention, and Policy, 17(1), 40. https://doi.org/10.1186/s13011-022-00474-2
   PubMed Web of Science ®Google Scholar
• Larney, S., Zador, D., Sindicich, N., & Dolan, K. (2017). A qualitative study of reasons for seeking and ceasing opioid substitution treatment in prisons in New South Wales, Australia. Drug and Alcohol Review, 36(3), 305–310. https://doi.org/10.1111/dar.12442
   PubMed Web of Science ®Google Scholar
• Lintzeris, N., Dunlop, A. J., Haber, P. S., Lubman, D. I., Graham, R., Hutchinson, S., Arunogiri, S., Hayes, V., Hjelmström, P., Svedberg, A., Peterson, S., & Tiberg, F. (2021). Patient-reported outcomes of treatment of opioid dependence with weekly and monthly subcutaneous depot vs daily sublingual buprenorphine: A randomized clinical trial. JAMA Network Open, 4(5), e219041–e219041. https://doi.org/10.1001/jamanetworkopen.2021.9041
   PubMed Web of Science ®Google Scholar
• Lofwall, M. R., Walsh, S. L., Nunes, E. V., Bailey, G. L., Sigmon, S. C., Kampman, K. M., Frost, M., Tiberg, F., Linden, M., Sheldon, B., Oosman, S., Peterson, S., Chen, M., & Kim, S. (2018). Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial. JAMA Internal Medicine, 178(6), 764–773. https://doi.org/10.1001/jamainternmed.2018.1052
   PubMed Web of Science ®Google Scholar
• Shepherd, S. M., Spivak, B., Ashford, L. J., Williams, I., Trounson, J., & Paradies, Y. (2020). Closing the (incarceration) gap: Assessing the socio-economic and clinical indicators of indigenous males by lifetime incarceration status. BMC Public Health, 20(1), 1–14. https://doi.org/10.1186/s12889-020-08794-3
   PubMed Web of Science ®Google Scholar
• Sheppard, A., & Ricciardelli, R. (2020). Employment after prison: Navigating conditions of precarity and stigma. European Journal of Probation, 12(1), 34–52. https://doi.org/10.1177/2066220320908251
   Web of Science ®Google Scholar
• Simojoki, K., Vorma, H., & Alho, H. (2008). A retrospective evaluation of patients switched from buprenorphine (subutex) to the buprenorphine/naloxone combination (suboxone). Substance Abuse Treatment, Prevention, and Policy, 3(1), 1–6. https://doi.org/10.1186/1747-597X-3-16
   PubMedGoogle Scholar
• Spittal, M., Forsyth, S., Borschmann, R., Young, J., & Kinner, S. (2019). Modifiable risk factors for external cause mortality after release from prison: A nested case–control study. Epidemiology and Psychiatric Sciences, 28(2), 224–233. https://doi.org/10.1017/S2045796017000506
   PubMed Web of Science ®Google Scholar
• Velasquez, M., Flannery, M., Badolato, R., Vittitow, A., McDonald, R. D., Tofighi, B., Garment, A. R., Giftos, J., & Lee, J. D. (2019). Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail. Addiction Science & Clinical Practice, 14(1), 1–12. https://doi.org/10.1186/s13722-019-0166-0
   PubMed Web of Science ®Google Scholar
• Waddell, E. N., Baker, R., Hartung, D. M., Hildebran, C. J., Nguyen, T., Collins, D. R. M., Larsen, J. E., & Stack, E. (2020). Reducing overdose after release from incarceration (ROAR): Study protocol for an intervention to reduce risk of fatal and non-fatal opioid overdose among women after release from prison. Health & Justice, 8(1), 1–19. https://doi.org/10.1186/s40352-020-00113-7
   PubMedGoogle Scholar
• Ziaaddini, H., Heshmati, S., Chegeni, M., Mousavi-Ramezanzade, M., & Mazhari, S. (2018). Comparison of Buprenorphine and Buprenorphine/naloxone in detoxification of opioid-dependent men. Addiction & Health, 10(4), 269.
   PubMedGoogle Scholar